Company intelligence / Profile preview

Climb Together

Massachusetts, United Stateslearnworkecosystemlibrary.com ↗

Ownership: Private
Employees: ~40
Development stage: Other

Overview

Climb Bio is advancing budoprutug, an anti-CD19 monoclonal antibody, in Phase 2 for primary membranous nephropathy and in Phase 1 for immune thrombocytopenia and systemic lupus erythematosus. A subcutaneous formulation is in preclinical development. The company also has CLYM116, an anti‑APRIL monoclonal antibody licensed from Mabworks, currently in IND-enabling studies for IgA nephropathy. No clinical results have been published yet; preclinical data on CLYM116 are expected later in 2025.

Therapeutic areas: ImmunologyNephrologyHematology
Modalities: Monoclonal antibodyBiologic
Industry: Biotech

Partnerships

Beijing Mabworks Biotech Co., Ltd. (licensing partner for CLYM116)

Beyond the preview

Go deeper on Climb Together.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Climb Together.

Explore the full profile